Annandale, VA; March 10, 2022
An important clinical study for people with recurrent Clostridium difficile (c Diff) infection
The leaders and researchers at the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) are very pleased to announce their collaboration with Ferring Pharmaceuticals Inc. for a pivotal, new research study addressing recurrent Clostridium difficile infection (C. diff or CDI). This study will involve treating these infections with a novel fecal transplant compound, RBX2660, an enema-based material derived from healthy stool donors.
“A new investigational Microbiota Restoration Therapy (MRT™), the RBX2660 formulation (a microbiota-based live biotherapeutic), will be the foundation for this study”, stated Executive Director, Steve Poretz. “Fecal transplantation isn’t a new technique. But the approach and formulation Ferring and Rebiotix are using is a somewhat unique approach. Because C. diff is a very difficult condition to treat, we are anticipating this novel therapy will produce greater participation among the community of C. diff patients. For this study there will not be a placebo meaning all participates will receive the actual treatment therapy”